Table 1.
Baseline Characteristics of Newly Diagnosed Therapy-Naive Human Immunodeficiency Virus-Infected Patients in the SPREAD Program
| Characteristic | All (N = 9588) | 2002–2005 (n = 2990) | 2006–2007 (n = 2458) | 2008–2010 (n = 4140) | P Value |
|---|---|---|---|---|---|
| Male sex | 7695 (80.3) | 2337 (78.2) | 1952 (79.4) | 3406 (82.3) | .0001 |
| Age at diagnosis, y, median (IQR) | 37 (29–43) | 38 (29–42) | 36 (29–42) | 37 (29–43) | NS |
| Transmission risk group | <.0001 | ||||
| MSM | 4969 (51.8) | 1486 (49.7) | 1169 (47.6) | 2314 (55.9) | |
| Heterosexual | 3195 (33.3) | 1060 (35.5) | 812 (33.0) | 1323 (32.0) | |
| Injecting drug user | 607 (6.3) | 245 (8.2) | 174 (7.1) | 188 (4.5) | |
| Continent of origin | <.0001 | ||||
| Western Europe | 5072 (52.9) | 1823 (61.0) | 1270 (51.7) | 1979 (47.8) | |
| Central and Eastern Europe | 1719 (17.9) | 561 (18.8) | 534 (21.7) | 624 (15.1) | |
| Sub-Saharan Africa | 735 (7.7) | 377 (12.6) | 161 (6.6) | 197 (4.8) | |
| HIV RNA load, log copies/mL, median (IQR) | 4.8 (4.2–5.3) | 4.9 (4.3–5.3) | 4.8 (4.2–5.3) | 4.8 (4.2–5.3) | .002 |
| CD4 count, cells/µL, median (IQR) | 391 (193–544) | 355 (180–547) | 360 (192–535) | 393 (202–544) | NS |
| CDC stage at diagnosis | .0005 | ||||
| A or B | 6860 (71.5) | 2460 (82.3) | 1567 (63.8) | 2833 (68.4) | |
| C | 871 (9.1) | 360 (12.0) | 209 (8.5) | 302 (7.3) | |
| Subtype | <.0001 | ||||
| A | 632 (6.6) | 234 (7.8) | 174 (7.1) | 224 (5.4) | |
| B | 6310 (65.8) | 2010 (67.2) | 1519 (61.8) | 2781 (67.2) | |
| C | 552 (5.8) | 190 (6.4) | 141 (5.7) | 221 (5.3) | |
| 01_AE | 309 (3.2) | 100 (3.3) | 87 (3.5) | 122 (2.9) | |
| 02_AG | 484 (5.0) | 135 (4.5) | 104 (4.2) | 245 (5.9) | |
| G | 107 (1.1) | 49 (1.6) | 23 (0.9) | 35 (0.8) | |
| F | 212 (2.2) | 29 (1.0) | 72 (2.9) | 111 (2.7) |
Data are presented as No. (%) unless otherwise specified.
Abbreviations: CDC, Centers for Disease Control and Prevention; HIV, human immunodeficiency virus; IQR, interquartile range; MSM, men who have sex with men; NS, not significant (P value >.05).